Complete Response of Severe Symptomatic Bone Marrow Metastases from Heavily Pretreated Breast Cancer with A 3-Weekly Trastuzumab Schedule. A Clinical Case

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 317-319

  Rossi, Antonio ^a   Colantuoni, Giuseppe ^a   Cantore, Nicola ^a   Panico, Luigi ^a   De Chiara, Giovanni ^a   Ferbo, Umberto ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Bone marrow metastases; Metastatic breast cancer; Trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; LETROZOLE; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; DRUG INHIBITION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; LUNG METASTASIS; ONCOGENE NEU; PANCYTOPENIA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 1442301631     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Press MF, Jones LA, Godolphin W et al: HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 354A: 209-221, 1990.
2. Slamon DJ, Godolphin W, Jones LA et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Liu Y, El-Ashry D, Chen D et al: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34: 97-117, 1995.
4. Ragaz J, Brodie A, Jelovac D et al: Expression of COX2, aromatase, HER-2/neu and their correlation with the long-term outcome of 930 stage I-III breast cancer (BrCa) patients. Results from the British Columbia (BC) Tissue Micro-Array Project (BCTMAP). Proc Am Soc Clin Oncol 22: 3 (abstr. 9), 2003.
5. Hortobagyi GN: Options for treatment of metastatic breast cancer. In: ASCO Educational Book, 1990, pp. 515-521.
6. Hudziak RM, Lewis GD, Winget M et al: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172, 1989.
7. Cobleigh MA, Vogel CL, Tripathy D et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
8. Slamon DJ, Leyland-Jones B, Shak S et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. New Engl J Med 344: 783-792, 2001.
9. Kasimir-Bauer S, Oberhoff C, Schindler AE and Seeber S: A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols. Int J Oncol 20: 1027-1034, 2002.
10. Perez EA: Current management of metastatic breast cancer. Sem Oncol 26 (Suppl. 12): 1-10, 1999.
11. Shak S: Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Sem Oncol 26 (Suppl. 12):71-77, 1999.
12. Carbonell Castellon X, Castaneda-Soto NJ, Clemens M et al: Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study. Proc Am Soc Clin Oncol 21: 19a (abstr. 73), 2002.